Clinical Trial Update: Fecal Microbiota Transfer in Liver Cancer to Overcome Resistance to Atezolizumab/Bevacizumab (FLORA) [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial (FLORA) is evaluating fecal microbiota transfer to overcome resistance to atezolizumab/bevacizumab in hepatocellular carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Atezolizumab (atezolizumab)
• Bevacizumab (bevacizumab)

Snippet

Sponsor: Michael Dill | Conditions: Immunotherapy, HCC - Hepatocellular Carcinoma | Phase 2 | Status: RECRUITING